Real-world antipsychotic prescribing pathways and treatment modifications in schizophrenia spectrum disorders: evidence from the United Arab Emirates
Frontiers in Pharmacology · 29.05.2026 · 17
DOI: 10.3389/fphar.2026.1808636 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 29.05.2026. Verfasst von Syed Ali Bokhari und 3 weiteren Autor:innen. Beteiligte Einrichtung: Al Amal Psychiatric Hospital, Emirates Health Services, Dubai, United Arab Emirates. Die Arbeit nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Antipsychotic prescribing patterns in Gulf Cooperation Council countries remain poorly characterised despite distinctive challenges including workforce shortages, high expatriate populations, and cultural factors influencing treatment engagement. This study characterised antipsychotic prescribing pathways in the largest Gulf-region cohort to date.
Methods
This retrospective cohort study analysed electronic medical records of 5,125 patients with schizophrenia spectrum disorders (ICD-10 F20–F29) treated at Al Amal Psychiatric Hospital, Dubai, United Arab Emirates, between January 2018 and December 2025. Six domains were examined: first-line antipsychotic selection, treatment persistence, treatment modifications, long-acting injectable(s) (LAI) utilisation, clozapine prescribing, and antipsychotic polypharmacy. Kaplan–Meier survival analysis, Cox proportional hazards models, and logistic regression were employed, with propensity-score weighting for class comparisons.
Results
The cohort (62.7% male; mean age 33.3 years) represented 120 nationalities. First-generation antipsychotics comprised 43.8% of all first-line prescriptions (predominantly intramuscular haloperidol), but second-generation antipsychotics accounted for 90.4% of first-line oral prescriptions, with olanzapine (43.5%) and risperidone (25.3%) predominating. Median persistence on the first oral antipsychotic was 36 days; only 23.0% remained at 12 months. Propensity-score weighted analysis confirmed a persistence disadvantage for oral first-generation antipsychotics (HR 1.43, 95% CI 1.21–1.70), largely attributable to haloperidol bridging therapy. Treatment modifications occurred in 60.1% of patients, with a median of 3 distinct antipsychotics (IQR 2–4), rising to 4 (IQR 3–5) in treatment-resistant patients. LAI utilisation was 34.1%, driven by treatment-resistant cases (55.3% vs 20.3%). Among 2,028 patients meeting treatment-resistant schizophrenia criteria (39.6%), only 7.8% received clozapine, with a median delay of 10.2 months from eligibility and 26.7% initiated within 3 months. Oral polypharmacy affected 42.9% of patients; cross-sectional point prevalence (20%–22%) was below global benchmarks. Benzodiazepine co-prescribing (79.8%) exceeded most international comparators, partly reflecting the acute inpatient setting and longitudinal measurement. Ethnic variation was observed across prescribing domains, and LAI initiation accelerated 19-fold in 2024–2025 versus 2018–2020.
Conclusion
While oral first-line prescribing aligns with international guidelines, the findings highlight poor treatment persistence, substantial clozapine underutilisation, high longitudinal polypharmacy despite cross-sectional rates below international benchmarks, and ethnic variation across one of the world’s most diverse populations, identifying specific targets for quality improvement in Gulf psychiatric settings.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Al Amal Psychiatric Hospital, Emirates Health Services, Dubai, United Arab Emirates.
- Department of Psychiatry, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates.
- Department of Psychiatry, Faculty of Medicine, University of Khartoum, Khartoum, Sudan.
- Department of Psychiatry, Al Ain Hospital, SEHA, Al Ain, United Arab Emirates.
Zitieren
APA
Bokhari, S. A., Elnoor, M., Javaid, S. F., & Alnor, M. A. (2026). Real-world antipsychotic prescribing pathways and treatment modifications in schizophrenia spectrum disorders: evidence from the United Arab Emirates. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1808636
Vancouver
Bokhari SA, Elnoor M, Javaid SF, Alnor MA. Real-world antipsychotic prescribing pathways and treatment modifications in schizophrenia spectrum disorders: evidence from the United Arab Emirates. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1808636
BibTeX
@article{Bokhari2026,
author = {Bokhari, Syed Ali and Elnoor, Muhanad and Javaid, Syed Fahad and Alnor, Mohamed A},
title = {Real-world antipsychotic prescribing pathways and treatment modifications in schizophrenia spectrum disorders: evidence from the United Arab Emirates},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1808636}
}
EUVIMED